SHERIDAN, WYOMING -- July 10, 2026 -- The Rosen Law Firm has announced a July 27, 2026 deadline for investors who purchased Zoetis Inc. securities between January 14, 2025 and May 6, 2026 to seek appointment as lead plaintiff in a securities fraud class action lawsuit. The firm reminds purchasers of Zoetis shares during this period that they may be entitled to compensation through a contingency fee arrangement, requiring no upfront payment. Investors with losses exceeding $100,000 have the opportunity to direct the litigation as lead plaintiff representatives.
Class Action Centers on Alleged Misrepresentations About Companion Animal Product Performance
The lawsuit alleges that Zoetis made false or misleading statements throughout the class period regarding its flagship Companion Animal products. According to the complaint, the company touted growing market share, strong veterinarian adoption, and accelerating sales growth while failing to disclose material weaknesses in key product lines. The alleged misrepresentations covered three major product categories that form a significant portion of Zoetis' companion animal portfolio.
Librela Faced Weakening Veterinarian Adoption Following FDA Safety Warnings
The lawsuit claims Zoetis failed to disclose that veterinarian prescription growth and adoption of Librela, its canine pain treatment, were sharply weakening. Clinicians reportedly became more cautious following FDA safety warnings concerning serious neurological complications in dogs treated with the product. This information, when it eventually entered the market, allegedly caused investor damages. The complaint suggests the company continued promoting strong adoption metrics while veterinarian prescribing patterns were deteriorating.
Simparica Trio Lost Market Share to Lower-Priced Competitor
Zoetis' Simparica Trio parasiticide product line allegedly lost significant market share to a competing canine treatment. The competitor offered lower pricing and broader indicated use in what the lawsuit describes as a slowing overall market. The company allegedly failed to disclose this competitive pressure while publicly emphasizing strong performance across its product portfolio. Market dynamics shifted against Simparica Trio during the class period, according to the complaint.
Dermatology Products Apoquel and Cytopoint Faced New Competition
The lawsuit further alleges that Zoetis' dermatology products, Apoquel and Cytopoint, were losing substantial market share to a newly launched competing canine treatment. These products represent important revenue contributors within the companion animal segment. The company allegedly continued to project strength in this category while competitive erosion was occurring. When accurate market share data became public, investors allegedly suffered losses.
Lead Plaintiff Appointment Requires Action by July 27 Deadline
Investors seeking to serve as lead plaintiff must file a motion with the court no later than July 27, 2026. A lead plaintiff acts as a representative party on behalf of other class members in directing the litigation. The Rosen Law Firm emphasizes that no class has been certified yet. Until certification occurs, investors are not represented by counsel unless they retain one independently. Investors may select counsel of their choice, serve as lead plaintiff, or remain absent class members. The ability to share in any potential future recovery does not depend on serving as lead plaintiff.
Rosen Law Firm Highlights Securities Class Action Track Record
The Rosen Law Firm concentrates its practice in securities class actions and shareholder derivative litigation, representing investors globally. The firm achieved the largest ever securities class action settlement against a Chinese company. ISS Securities Class Action Services ranked Rosen Law Firm number one for securities class action settlements in 2017. The firm has been ranked in the top four each year since 2013 and has recovered billions of dollars for investors. In 2019 alone, the firm secured over $438 million for investors. Founding partner Laurence Rosen was named by Law360 as a Titan of Plaintiffs' Bar in 2020.
Investors who purchased Zoetis securities during the class period and wish to join the class action or discuss their options can visit https://rosenlegal.com/cases/zoetis-inc/join or contact Phillip Kim, Esq. toll-free at 866-767-3653.